Fennec Pharmaceuticals Inc. (FENC) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Research Triangle Park, NC, 美国. 現任CEO為 Robert C. Andrade.
FENC 擁有 IPO日期為 2017-09-15, 32 名全職員工, 在 NASDAQ Capital Marke, 市值為 $185.77M.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
